drug

lacutamab

Phase 2updated 3mo ago

by $IPHA Innate Pharma SA

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying lacutamab

phase2Study of Lacutamab in Peripheral T-cell Lymphomarecruitingn=56
phase1Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2completedn=20

News(1)

Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
Sobi has bought into Innate Pharma’s vision for lacutamab, handing the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.
fiercebiotech · 7d ago

Data sources

ClinicalTrials.gov

last refreshed 16m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

lacutamab

Phase 2updated 3mo ago

by $IPHA Innate Pharma SA

Phase 2

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying lacutamab

phase2Study of Lacutamab in Peripheral T-cell Lymphomarecruitingn=56
phase1Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2completedn=20

News(1)

Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push
Sobi has bought into Innate Pharma’s vision for lacutamab, handing the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.
fiercebiotech · 7d ago

Data sources

ClinicalTrials.gov

last refreshed 16m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

lacutamab

all catalysts(0)

Trials studying lacutamab

News(1)

Report a data issue

comments(0)

lacutamab

all catalysts(0)

Trials studying lacutamab

News(1)

Report a data issue

comments(0)